Paper39745907
Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide.
Guerra G and 19 others. Neuro Oncol, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide. Papers, record 39745907. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39745907
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glioma | Major topic |
| Brain Neoplasms | Major topic |
| Antineoplastic Agents, Alkylating | Major topic |
| DNA Repair | Major topic |
| Polymorphism, Single Nucleotide | Major topic |
| Germ-Line Mutation | Major topic |
| DNA Damage | Major topic |
| Humans | |
| Temozolomide | |
| Male | |
| Female | |
| Middle Aged | |
| Adult | |
| Prognosis | |
| Survival Rate | |
| Aged | |
| Follow-Up Studies | |
| Biomarkers, Tumor | |
| Young Adult | |
| DNA Repair Enzymes |
Source PubMed
Grants25
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA139020 | NCI NIH HHS | United States | R01CA139020 | PubMed and NIH | NIH RePORTER |
| R01 CA126831 | NCI NIH HHS | United States | R01CA126831 | PubMed and NIH | NIH RePORTER |
| UL1 RR024131 | NCRR NIH HHS | United States | UL1RR024131 | PubMed and NIH | NIH RePORTER |
| loglio Collective | PubMed | PubMed | |||
| P50 CA097257 | NCI NIH HHS | United States | P50CA097257 | PubMed and NIH | NIH RePORTER |
| P30 CA015083 | NCI NIH HHS | United States | P30CA015083 | PubMed | NIH RePORTER |
| National Brain Tumor Society | PubMed | PubMed | |||
| Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries | PubMed | PubMed | |||
| National Cancer Institute's Surveillance, Epidemiology and End Results Program | PubMed | PubMed | |||
| NCATS NIH HHS | United States | PubMed | PubMed | ||
| Mayo Clinic | PubMed | PubMed | |||
| R01 CA052689 | NCI NIH HHS | United States | R01CA052689 | PubMed and NIH | NIH RePORTER |
| National Brain Tumor Foundation | PubMed | PubMed | |||
| Ting Tsung and Wei Fong Chao Foundation | PubMed | PubMed | |||
| Stanley D. Lewis and Virginia S. Lewis Endowed Chair in Brain Tumor Research | PubMed | PubMed | |||
| T32CA112355 | NIH HHS | United States | T32CA112355 | PubMed and NIH | NIH RePORTER |
| T32 CA112355 | NCI NIH HHS | United States | T32CA112355 | PubMed and NIH | NIH RePORTER |
| P50CA097257 | NIH HHS | United States | P50CA097257 | PubMed and NIH | NIH RePORTER |
| R01CA126831 | NIH HHS | United States | R01CA126831 | PubMed and NIH | NIH RePORTER |
| R01CA139020 | NIH HHS | United States | R01CA139020 | PubMed and NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Update of | 39417102 |
Source PubMed
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19578366 | Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. | Nat Genet | 2009 | https://conductscience.org/library/papers/19578366 | PubMed |
| 2 | 26854917 | Integrative approaches for large-scale transcriptome-wide association studies. | Nat Genet | 2016 | https://conductscience.org/library/papers/26854917 | PubMed |
| 3 | 25910840 | The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. | Neuro Oncol | 2015 | https://conductscience.org/library/papers/25910840 | PubMed |
| 4 | 9776413 | Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. | J Natl Cancer Inst | 1998 | https://conductscience.org/library/papers/9776413 | PubMed |
| 5 | 30446622 | Domain analysis of PNKP-XRCC1 interactions: Influence of genetic variants of XRCC1. | J Biol Chem | 2019 | https://conductscience.org/library/papers/30446622 | PubMed |
| 6 | 22532597 | STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. | Mol Cancer Ther | 2012 | https://conductscience.org/library/papers/22532597 | PubMed |
| 7 | 19179423 | Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. | Neuro Oncol | 2009 | https://conductscience.org/library/papers/19179423 | PubMed |
| 8 | 32386320 | Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C. | Neuro Oncol | 2020 | https://conductscience.org/library/papers/32386320 | PubMed |
| 9 | 28346443 | Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. | Nat Genet | 2017 | https://conductscience.org/library/papers/28346443 | PubMed |
| 10 | 12243247 | Toll-like receptor 9, CpG DNA and innate immunity. | Curr Mol Med | 2002 | https://conductscience.org/library/papers/12243247 | PubMed |
| 11 | 20649466 | Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. | Antioxid Redox Signal | 2011 | https://conductscience.org/library/papers/20649466 | PubMed |
| 12 | 32901889 | PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. | Oncol Rep | 2020 | https://conductscience.org/library/papers/32901889 | PubMed |
| 13 | 32166314 | MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. | Neuro Oncol | 2020 | https://conductscience.org/library/papers/32166314 | PubMed |
| 14 | 39090080 | TNC upregulation promotes glioma tumourigenesis through TDG-mediated active DNA demethylation. | Cell Death Discov | 2024 | https://conductscience.org/library/papers/39090080 | PubMed |
| 15 | 26336131 | Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. | Oncotarget | 2015 | https://conductscience.org/library/papers/26336131 | PubMed |
| 16 | 35550063 | The immunogenetics of viral antigen response is associated with subtype-specific glioma risk and survival. | Am J Hum Genet | 2022 | https://conductscience.org/library/papers/35550063 | PubMed |
| 17 | 34337348 | Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. | Cancer Drug Resist | 2021 | https://conductscience.org/library/papers/34337348 | PubMed |
| 18 | 18997474 | Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. | Neuroepidemiology | 2009 | https://conductscience.org/library/papers/18997474 | PubMed |
| 19 | 23038810 | Alkylation sensitivity screens reveal a conserved cross-species functionome. | Mol Cancer Res | 2012 | https://conductscience.org/library/papers/23038810 | PubMed |
| 20 | 30395168 | gwasurvivr: an R package for genome-wide survival analysis. | Bioinformatics | 2019 | https://conductscience.org/library/papers/30395168 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41892810 | Genomic Impacts of Biological Exposures. | J Dev Biol | 2026 | https://conductscience.org/library/papers/41892810 |
Source PubMed
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IDH1 | 3417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
| MGMT | 4255 | PubTator's text mining | https://conductscience.org/library/genes/4255 | NCBI Gene |
| MSH5 | 4439 | PubTator's text mining | https://conductscience.org/library/genes/4439 | NCBI Gene |
| NEIL2 | 252969 | PubTator's text mining | https://conductscience.org/library/genes/252969 | NCBI Gene |
| PARP3 | 10039 | PubTator's text mining | https://conductscience.org/library/genes/10039 | NCBI Gene |
| PNKP | 11284 | PubTator's text mining | https://conductscience.org/library/genes/11284 | NCBI Gene |
| TDG | 6996 | PubTator's text mining | https://conductscience.org/library/genes/6996 | NCBI Gene |
| UNG | 7374 | PubTator's text mining | https://conductscience.org/library/genes/7374 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39745907
GET https://conductscience.org/api/papers/v1/39745907/grants?page=2